Pasko,deborah cv.04.14 for linkedin pdf

  • 201 views
Uploaded on

 

More in: Healthcare
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
201
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
4
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. DEBORAH A. PASKO, PHARMD, MHA dag0415@gmail.com Curriculum Vitae ADDRESS Office University of Michigan Health System 300 N. Ingalls NIB 4D18, SPC 5475 Ann Arbor, MI 48109-5475 Telephone: (734) 936-9387 E-mail: dapasko@med.umich.edu Residence: 573 Landings Blvd Ann Arbor, MI 48103 Mobile # 734-497-6988 Email: dag0415@gmail.com Licensure: State of Michigan License # 5302031606 EDUCATION 09/2008 – 02/11 Masters of Health Administration Walden University School of Health Sciences Minneapolis, MN 2001-2003 Nephrology/Critical Care Fellowship College of Pharmacy University of Michigan Preceptor: Bruce A. Mueller, PharmD 1998-2001 Doctor of Pharmacy College of Pharmacy Idaho State University 1989-1995 Bachelor of Science, Pharmacy College of Pharmacy Ohio Northern University
  • 2. Deborah A. Pasko, PharmD, MHA 2 EMPLOYMENT EXPERIENCE 1/2012-present Clinical Specialist and Sr. Project Manager for Administration Children’s and Women’s Administration CS Mott Children’s Hospital and Von Voigtlander Women’s Hospital University of Michigan Health System 05/15-present Intermittent Consultant, Medication safety Joint Commission Resources Oakbrook Terrace, IL 09/2009 – present LEAN coach C.S. Mott Children’s Hospital and Von Voigtlander Women’s Hospital Mott Administration Team University of Michigan Health System, Ann Arbor, MI 09/2008-present Adjunct Clinical Associate Professor Department of Clinical Sciences University of Michigan, College of Pharmacy, Ann, Arbor, MI 05/2009 – 12/2011 Project Manager, Children’s and Women’s Replacement Hospital Project C. S. Mott Hospital Administration Team C. S. Mott Children’s Hospital and Von Voigtlander Women’s Hospital University of Michigan Health System, Ann Arbor, MI 03/2004-05/2009 Clinical Coordinator, Mott Pharmacy C.S. Mott Children’s Hospital Department of Pharmacy Services University of Michigan Health System, Ann Arbor, MI 09/2003-05/2009 Clinical Pharmacy Specialist, Pediatric Critical Care Department of Pharmacy Services University of Michigan Health System, Ann Arbor, MI 07/2003 – 09/2008 Adjunct Clinical Assistant Professor Department of Clinical Sciences College of Pharmacy University of Michigan, Ann Arbor, MI 09/2001-07/2003 Clinical Instructor Department of Clinical Sciences College of Pharmacy University of Michigan, Ann Arbor, MI
  • 3. Deborah A. Pasko, PharmD, MHA 3 12/1997-8/2003 Pediatric Pharmacist C.S. Mott Children's Hospital University of Michigan Health System, Ann Arbor, MI 09/1997-11/1997 Staff Pharmacist St. Joseph’s Mercy Hospital, Ann Arbor, MI 08/1995-09/1997 Staff Pharmacist St. Rita’s Medical Center, Lima, OH 06/1992-08/1995 Pharmacy Intern St. Rita’s Medical Center, Lima, OH LEADERSHIP TRAINING 09/2013 – 05/2014 Advanced Leadership Program Center for the Advancement of Women University of Michigan 08/2013 OCHSPS Wave 2 Error Prevention and Leadership Methods Ohio Collaborative Hospitals Solutions for Patient Safety Riley Children’s Hospital Indianapolis, IN 05/2013 Leadership Essentials 5 day course for leaders at UMHS University of Michigan Health System, Ann Arbor, MI 02/2013 UMHS Conference: Developing Leaders and the Best One day conference Ann Arbor, MI 09/2009 LEAN Healthcare Course University of Michigan Health System Quality Improvement http://www.med.umich.edu/i/quality/edu/healthcare_course.html University of Michigan Health System, Ann Arbor, MI 10/2008 Manager’s Bootcamp One day symposium: 13th Annual American Society of Health System Pharmacy Chicago, IL Addressing Key Issues in Health-System Pharmacy: Spotlight on Leadership Two day conference: 10/20-10/21/2008 10/2007 Management Skills for New Clinical and Operational Leaders
  • 4. Deborah A. Pasko, PharmD, MHA 4 One day symposium: 12th Annual American Society of Health System Pharmacy Chicago, IL 10/2007 Scanning the Radar of Health-System Pharmacy: Developing Strategies and Tools for Successful Leadership Two day conference: 10/15-10/16/2007 01/2005 – 03/2005 The Edge: Foundations for Successful Leadership 10 week course for new managers and supervisors University of Michigan Health System TECHNICAL TRAINING 05/2013 Epic Willow Fundamentals 3 day course Epic Headquarters Verona, Wisconsin 03/2013 Epic Beacon Fundamentals 2 day course Epic Headquarters Verona, Wisconsin 02/2013 Epic Inpatient Fundamentals 3 day course Epic Headquarters Verona, Wisconsin C&W HOPSITAL ADMINISTRATION SR. PROJECT MANAGER AND CLINICAL SPECIALIST RESPONSIBILITIES (CURRENT) Health System:  Project Manager, MiChart, Children’s and Women’s Hospitals (C&W) , University of Michigan Hospital and Health Systems  Work closely with all medical disciplines to transition the inpatient areas into the new MiChart, Epic system  Facilitate pediatric oncology and BMT MiChart work and deadlines  Adoption network and change facilitator  Subject Matter Expert (SME) for Children’s and Women’s administration team  Leader for pediatric medication management and Beacon inpatient workflow  Committees: UMHS MiChart Leadership team, BCMA, Communications, Medication Advisory Council, Beacon order set build and review, MiChart Change Network  Administrative expert for Joint Commission initiatives, policies and procedures
  • 5. Deborah A. Pasko, PharmD, MHA 5  Project lead for MedEx 3500 syringe pump updates and pushes  Project co-lead for C&W implementation of CareFusion large volume IV pumps  Assist Associate Hospital Director with hospital emergency preparedness Administrative:  Work closely with Executive Director, Associate Hospital Director, and Nursing Director to set hospital goals, short and long term strategy, and manage day to day operations  Member of the C&W leadership team that guides our current strategic goals: Quality and Safety, Access, Capacity and Staffing, Financial Stewardship, and MiChart  This team reviews all monthly hospital metrics including financial status reports  Administrative liaison for MCIT (including Secondary Alert Notification System), Biomed, Pharmacy services, Laboratory, Radiology, Respiratory Care, Survival Flight/SWAT, ECMO, other clinical support departments  Participate in UMHS Hospital Administrator on-call (AOC) support Clinical:  Oversee, facilitate, or support all clinical initiatives within the Children’s and Women’s Hospitals  Continued clinical support for Eclipsys and Centricity systems  Oversee and facilitate clinical initiatives with adult patient areas in the Children’s and Women’s Hospital such as Adult Bone Marrow Transplant, Adult Leukemia, two adult surgical services  Administrative lead for CPR/RRT response in C&W, including adult response Quality and Safety:  Safety co-lead, C&W  Secondary facilitator daily safety huddle  Lead, participate, facilitate Ohio Collaborative HAC groups such as Adverse Drug Events (ADE), Serious Safety Events (SSE’s), Ventilator Associated Pneumonia (VAP), Central Line Associated Blood Stream Infections (CLABSI)  Participate in all serious safety event reviews  Member of safety scoring team, medication and non-medication events  Administrative lead for pilot huddle initiative on ADE work within daily management huddle for PICU  Chair, Pediatric Medication Safety Committee, subcommittee of P&T  Michigan Health Administration (MHA) safety round-table participant LEAN  Lead, facilitate, participate clinical LEAN initiatives  Member of all LEAN coach committee, Michigan Quality Services  Current projects: 1. Bed placement and throughput document for C&W hospital (lead) 2. Use of fluoroscopy for ECMO cannulation (lead) 3. Standardization of continuous infusion concentrations between C&W, UH, CVC, and OR’s (co-lead) 4. Improving timing of antibiotic administration for fever and neutropenia patients in the emergency room (co-lead) 5. Continual work on the ideal patient experience (group coaches)
  • 6. Deborah A. Pasko, PharmD, MHA 6 6. Continual work on daily management huddles in various areas (pharmacy, PICU) INTERMITTENT CONSULTANT, MEDICATION SAFETY (CURRENT) JOINT COMMISSION RESOURCES AND JOINT COMMISSION INTERNATIONAL  Work with collaborative team to evaluate and recommend medication safety techniques to clients, both domestic and international  Mock surveyor  Co-presenter of IV safety medication workshop  Have now completed 2 day workshop in India (Mumbai, Pune, Kolkata, Hyderbad) and Barranquilla Colombia  Evaluate all aspects of medication safety including prescribing, procurement, dispensing, and administration for clients  Use and teach safety evaluation techniques such as RCA, FMEA, HPI tools in safety analyses for clients PROJECT MANAGER RESPONSIBILITIES FOR OPENINING OF NEW HOSPITAL (2009-2011)  Oversaw and facilitated operational and activation planning of the following areas for the CS Mott Children’s and VonVoigtlander Women’s Replacement Hospital:  Pediatric Intensive Care Unit  Pediatric Cardiothoracic Intensive Care Unit  Neonatal Intensive Care Unit  Pediatric Hematology/BMT area  Adult BMT area  Operating Room and Recovery area  EEG  Pharmacy  Respiratory Therapy  Adult Services  Extracorporeal Membrane Oxygenation Therapy Team  Emergency/Disaster Management  CPR and RRT  Adult Services  Regional Infectious Containment Unit  Departmental lead for IT meetings (helped IT decide design, device types (telecom, computers), and other IT needs for each department listed above)  Leader of replacement hospital projects including unified communications, bedside medication delivery, pharmacy medication managers, electronic nursing flow sheet, bedside bar-coding medication administration, workforce planning, and hospital simulations  Frequent presenter at town hall meetings
  • 7. Deborah A. Pasko, PharmD, MHA 7  Meet with hospital leadership team to keep abreast of new hospital projects and project status  Moved in new facility 12/4/2011 CLINICAL COORDINATOR RESPONSIBILITIES & ACCOMPLISHMENTS (2004-2009)  Position 80% clinical, 20% operational  Primary library builder and implementation lead for MedEx 3500 syringe pump initiative  Responsible for staff pharmacist education and development Oversee Patient Focused Care (PFC) pharmacists including performance evaluation  Liaison between staff and clinical pharmacists  Eliminated the “Rule of Six” and implemented standard concentrations in all pediatric patient care areas including the intensive care areas: Pediatric Cardiothoracic (PCTU), Pediatric Intensive Care (PICU), Neonatal Intensive Care (NICU), Trauma Burn Intensive Care (TBICU)  Created and implemented smart technology syringe pumps in all pediatric patient care areas  Developed protocols including: Pediatric/Neonatal Electrolyte Protocol, Factor Seven Guidelines, Continuous Insulin Infusions, Continuous Heparin Infusions  Pediatric clinical lead of “order sets” for our physician ordering system  Responsible for all pharmacy aspects of Continuous Renal Replacement Therapies for both adult and pediatric patients. This includes development of order forms, anticoagulation protocols, and purchasing and implementation of a commercial standard dialysate solution  Active role in Pediatric Medication Safety Committee and Med/Surgical Joint Practice PEDIATRIC INTENSIVE CARE (PICU) SPECIALIST RESPONSIBILITIES & ACCOMPLISHMENTS (2003-2009)  Participate in PICU multidisciplinary team daily rounds  Pharmacy consult for pediatric trauma burn patients  Develop and tailor pharmacotherapy regimens, goals, and assess outcomes for PICU patients  Extensive experience in pediatric patients supported by Extracorporeal Life Support (ECLS), Continuous Renal Replacement Therapies (CRRT), Intermittent hemodialysis, and Extracorporeal Liver Support (ELMO)  Extensive experience with pediatric cardiothoracic patients  Provide drug information relating to the PICU questions for nurses, physicians, pharmacists  Direct all pharmacokinetic monitoring for PICU patients  Document clinical interventions/recommendations in U of M pharmacy clinical computer program  Participate in weekly PICU grand round discussions, including journal club, fellow rounds, and monthly M&M
  • 8. Deborah A. Pasko, PharmD, MHA 8  Monthly orientation for medical students and residents  Pharmacy lead for PICU “order sets” for computer physician ordering system  Eliminated “Rule of Six” and implemented standard concentrations in the PICU  Created and implemented smart technology syringe pumps in the PICU  Developed sedation guidelines for the PICU  Created guidelines for the use of dexmedetomidine  Care for hematology/oncology and BMT patients transferred to the PICU  Care for transplant patients (kidney, liver, heart) PUBLICATIONS Long, MT, Wagner D, Maslach-Hubbard A, Pasko DA, Baldridge P, Annich, GM. Safety and efficacy of recombinant activated VII for refractory hemorrhage in pediatric patients on extracorporeal membrane oxygenation: as single center review. Perfusion 2013: DOI: 10.1177/0267659113499782. Mueller BA, Jasiak KS, Thiel SR, Stevenson JM, Vilay AM, Scoville BA, Churchwell MD, Pasko DA, Perkins N. Vibration enhances clearance of solutes with varying molecular weights during in vitro hemodialysis. ASAIO Journal. 59(2):140-4, 2013. Dickinson CJ, Wagner DS, Shaw BE, Owens, TA, Pasko DA, Niedner, MF. A Systematic Approach to Improving Medication Safety in a Pediatric Intensive Care Unit. Critical Care Nursing Quarterly 2012;35:15-26. Wagner D, Pasko D, Phillips K, Waldvogel J, Annich G. In Vitro Clearance of Dexmedetomidine in Extracorporeal Membrane Oxygenation. Perfusion 2012;28:40-46 Pasko DA, Churchwell MD, Salama NN, Mueller BA. Longitudinal Hemodiafilter Performance in Modeled Continuous Renal Replacement Therapy. Blood Purification 2011;32:82-88. Matzke GR, Aronoff CR, Atkinson AF Jr, Bennett WM, Deckers BS, Edkardt KU, Golper T, Grabe DW, Kasiske B, Keller F, Kielstein JT, Mehta R, Mueller BA, Pasko DA, Schaefer F, Sica DA, Inker LA, Umans JG, Murray P. Drug Dosing Consideration in patients with Acute and Chronic Kidney Disease-A Clinical Update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International 2011;80(11):1122-37. Wagner, D, Pasko D, Glenn D, Lapinski J, Callow L, Shaw B. The Medication Manager: Results of a Medications at the Bedside Pilot in a Pediatric Teaching Institution. Journal of Patient Safety 2010;6(2):76-79.
  • 9. Deborah A. Pasko, PharmD, MHA 9 Pasko, DA, Churchwell MD, Btaiche IF, Jain J, Mueller BA. Continuous Venovenous Hemodiafiltration Trace Element Clearance in Pediatric Patients: A Case Series. Pediatric Nephrology 2009; 24:807-13. Churchwell MD, Pasko DA, Smoyer WE, Mueller BA. Enhanced Clearance of Highly Protein Bound Drugs by Albumin-Supplemented Dialysate During Modeled Continuous Hemodialysis. Nephrology, Dialysis and Transplant 2009;24:231-8. Kaakeh Y, Phan H, DeSmet B, Pasko, DA, Glenn DK, Stevenson JG. Enhanced photoemission spectroscopy for verification of high-risk i.v. medications. American Journal of Health-System Pharmacy 2008;65:49-54. Taber SS, Pasko DA. The epidemiology of drug-induced disorders: the kidney. Review. Expert Opinon on Drug Safety 2008;7:679-90. Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, Pasko DA, & Smoyer WE. (2007). Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. 5th edition. Philadelphia. American College of Physicians. Churchwell MD, Pasko DA, Btaiche IF, Jinesh JC, Mueller BA. Trace elements removal during in vitro and in vivo continuous hemodialysis. Nephrology Dialysis Transplantation 2007;22:2970-2977. Cornell T, Wyrick P, Fleming G, Pasko DA, Han Y, Custer J, Haft J, Annich G. A case series describing the use of argatroban in patients on extracorporeal circulation. ASAIO Journal 2007;53:460-463. Churchwell MD, Pasko, DA, Mueller BA. Daptomycin transmembrane clearance in continuous hemofiltration and continuous dialysis with two different hemodiafilters. Blood Purification 2006;24:548-554 McBryde KD, Bunchman TE, Kudelka TL, Pasko DA, Brophy P. Hypertonic solutions in continuous renal replacement therapy for hyperosmolar acute renal failure. Pediatric Critical Care Medicine 2005;6:220-225. Nakamura AT, Btaiche I, Pasko DA, Jain JC, Mueller BA. In vitro clearance of trace elements via continuous renal replacement therapy. Journal of Renal Nutrition 2004 ;14 :214-219. Swartz R, Pasko DA, O’Toole J, Starmann B. Improving the delivery of continuous renal replacement therapy using regional citrate anticoagulation. Clinical Nephrology 2004;61:134-143.
  • 10. Deborah A. Pasko, PharmD, MHA 10 Kraft MD, Pasko DA, DePestel DD, Ellis JJ, et al. Clearance of linezolid during continuous veno-venous hemodiafiltration. Pharmacotherapy 2003;23:1071- 1075 Mueller BA, Pasko DA, Sowinski KM. Higher renal replacement therapy dose delivery influences on drug therapy. Artificial Organs 2003;27:808-814 Pasko DA, Mottes TA, Mueller BA. Pre-dialysis of blood prime in pediatric CRRT normalizes pH and electrolyte content. Pediatric Nephrology 2003;18:1177- 1183 Flynn JT, Pasko DA. Calcium Channel Blockers: Pharmacology and place in therapy of pediatric hypertension. Pediatric Nephrology 2000;15:302-316 Letters Churchwell MD, Btaiche IF, Pasko DA, Mueller BA. Reply letter: Trace elements removal during in vitro and in vivo continuous hemodialysis. Nephrology Dialysis Transplantation 2007;22:2970-2977. Mueller BA. Pasko DA. Sowinski KM. Ofloxacin clearance during continuous hemofiltration. [Comment. Letter] American Journal of Kidney Diseases 2003;42(6):1326-7; author reply 1327-8, 2003 Dec. HOSPITAL COMMITTEES 2012-present MiChart Leadership Team, phase 3 (MLT3), UMHS 2013-present Medication Advisory Committee (MAC), MiChart, UMHS 2013-present Bedside Barcode Medication Administration Committee, MiChart, UMHS 2013-present Beacon Orders Group, MiChart, UMHS 2012-present MiChart operational committee, Chair, C&W 2012-present Secondary Alert Notification Systems (SANS Steering and Operational Committee, Chair, C&W) 2012-present Quality and Safety Committee, C&W 2011-present CPR committee, C&W 2009-present Pediatric Medication Safety Committee, Chair, C&W 2009-present Adult Medication Safety Committee, UMHS 2004-present Pediatric Medical and Surgical Joint Practice Committee, UMHS 2010-2011 Bedside Barcode Medication Administration Committee, UMHS 2004-2009 Pediatric Medication Safety Committee, CS Mott Children’s Hospital 2003-2009 Pediatric Critical Care Joint Practice Committee, UMHS 2000-2012 Dialysis Standardization Committee, UMHS 1998-2001 Quality Improvement, UMHS 2000-2001 Chemo Focus Group, UMHS 1995-1997 Co-author; Pharmacy Newsletter, St. Rita's Medical Center
  • 11. Deborah A. Pasko, PharmD, MHA 11 Professional 2000-2001 Membership Committee, Pediatric Pharmacy Advocacy Group PRESENTATIONS 07/2013 “Improving IV Medication Practices for Patient Safety” Invited Co-Speaker, Joint Commission International Four, 2 day workshops Mumbai, Pune, Kolkata, and Hyderbad, India 10/2007 – present “Drug Adsorption and Distribution Challenges during ECMO” Invited speaker, UMHS ECMO lecture series Ann Arbor, MI 06/2011 “Pediatric Medication Committee: Not Just Another Committee” Invited Speaker, ASHP summer conference Denver, CO 04/2011 “Drug Dosing in Pediatric CKD/AKI Patients” Invited Speaker, National Kidney Foundation conference Las Vegas, NV 05/2009 “Calculating Drug Doses in AKI. Drug Prescribing in Kidney Disease – Initiative for Improved Dosing” Invited Speaker, KDIGO (Kidney Disease Improving Global Outcomes conference) Baltimore, MD 04/2008 "Safe Medication Administration-Titration, Loading doses and Avoiding Mistakes” Invited speaker, Pediatric Nursing 2008-Providing a Continuum of Care Ann Arbor, MI 02/2007 “Sedation in Children: From the Intensive Care Unit to Your Local Pharmacy” Invited speaker, Michigan Pharmacist Association Dearborn, MI 09/2005 “Pediatrics: Initiation Concerns and Pharmacy” Invited speaker, Midwest CRRT conference Indianapolis, IN 03/2005 “The Five Pillars of Pediatric Continuous Renal Replacement Therapy” Invited speaker, Pediatric Grand Rounds, University of Michigan Health System Ann Arbor, MI
  • 12. Deborah A. Pasko, PharmD, MHA 12 12/2004 “Anticoagulation Options for Continuous Renal Replacement Therapy” Invited speaker American Society of Hospital Pharmacists Orlando, FL 10/2004 “Anticoagulation Issues in Continuous Renal Replacement Therapy” Invited speaker American College of Clinical Pharmacy Dallas, TX 10/2004 “Longitudinal Solute Clearance in an In Vitro Continuous Hemofiltration Model” Invited Speaker, Platform Presentation American College of Clinical Pharmacy, Dallas, TX 10/2004 “Anticoagulation for CRRT” Invited speaker Toronto, Ontario, Canada 09/2004 “CRRT in Children: They’re Not Just Small Adults” Invited speaker Midwest CRRT Symposium Indianapolis, IN 07/2004 “Drug Dosing and Nutrition in Pediatric Continuous Renal Replacement Therapies” Invited speaker 3rd International Conference on Pediatric Continuous Renal Replacement Therapy Orlando, FL 05/2003-05/2009 Pharmacokinetics : A one-hour lecture for pediatric critical care fellows University of Michigan Health System 10/2003-05/2009 “CRRT”, Monthly PICU resident rounds University of Michigan Health System 09/2002 Nephrology Noon conference: Drug dosing in the elderly University of Michigan Health System 03/2002 “Everything you always wanted to know about dialysis but did not know who to ask” An one-hour lecture for pharmacy staff and students. University of Michigan Health System 07/2000 & 2001 "The Ins and Outs of Proper Order Writing" A one-hour lecture for residents/medical students. University of Michigan Health System PROFESSIONAL
  • 13. Deborah A. Pasko, PharmD, MHA 13 AFFILIATIONS 2000-present American Society of Health-System Pharmacists 2002-present Critical Care Medicine 2001-2008 American Society of Nephrology 1998-present Pediatric Pharmacy Advocacy Group AWARDS 2009 Pharmacy Practice Research Literature Award American Society of Hospital Pharmacy 2005 Pharmacist of the Year Southeastern Michigan Pharmacist Society 2003 Bayer Critical Care Fellow American College of Clinical Pharmacy TEACHING EXPERIENCE (College of Pharmacy, University of Michigan) 04/2003-present Preceptor for Pharmacy Residents, general and specialty 2005 – 2009 Elective Clerkship 693 & 694 Pediatric Critical Care 04/2004 P486 Pharmaceutical Care II 2001-2004 P510 Pharmaceutical Care III (Patient assignments and case presentations) 2003 Elective Clerkship 693 & 694 (P4 outpatient dialysis rotation) 2001-2001 P550 Opportunities in Pharmacy (Postgraduate training opportunities) 1997-2001 Introductory Clerkship 685 ABSTRACTS/POSTERS Pasko DA, Churchwell MD, Btaiche IF, Jain JC, Mueller BA. Trace Mineral Clearance in Pediatric Patients Supported by Continuous Venovenous Hemodiafiltration (CVVHDF). Blood Purification 2006;24:269
  • 14. Deborah A. Pasko, PharmD, MHA 14 Pasko DA, Btaiche IF, Jain JC, Mueller BA, Churchwell MD. Trace Element Clearance in Critically Ill Patients Treated with Continuous Venovenous Hemodiafiltration (CVVHDF). Blood Purification 2006;24:268 Cornell TT, Papez KE, Smoyer WE, Brophy PD, Mottes TA, Pasko DA. Thyroid Hormone Transmembrane Clearance During Continuous Venovenous Dialysis vs. Hemofiltration. Blood Purifications 2006;24:269-270 Cornell TT, Papez KE, Smoyer WE, Brophy PD, Mottes TA, Pasko DA. Thyroid Hormone Transmembrane Clearance During Therapeutic Plasma Exchange. Blood Purification 2006;24:270-271 Churchwell MD, Pasko DA, WE Smoyer, Mueller BA. Albumin-Supplemented Dialysate Enhances Clearance of Carbamazepine (CBZ) with In Vitro Continuous Venovenous Hemodialysis (CVVHD). Presented at American Society of Nephrology, 2005 Churchwell MD, Pasko DA, Grio M, Smoyer WE, Mueller BA. Albumin- Supplemented Dialysate Does Not Enhance Clearance of Phenytoin (PHT) with In Vitro Continuous Venovenous Hemodialysis (CVVHD). Presented at American Society of Nephrology, 2005, Abstract # TH-PO620 Churchwell MD, Pasko DA, Smoyer WE, Mueller BA. Albumin-Supplemented Dialysate Enhances Clearance of Valproic Acid (VPA) with In Vitro Continuous Venovenous Hemodialysis (CVVHD). Presented at American Society of Nephrology, 2005 Pasko DA, Grio M, Thomas S, Motttes T, Brophy PD. Methotrexate Transmembrane Clearance During Albumin Based Continuous Venovenous Hemodialysis. Blood Purification 2005;23:165. Churchwell MD, Pasko DA, Mueller BA. CVVHD Transmembrane Clearance of Daptomycin with Two Different Hemodiafilters. Presented at ICAAC in Washington, D.C, 2004 Churchwell MD, Pasko DA, Mueller BA. CVVH Transmembrane Clearance of Daptomycin with Two Different Hemodiafilters. Presented at ICAAC in Washington, D.C, 2004 Pasko DA, Annich GM. Phenobarbital Pharmacokinetics of an Infant on ECMO and CVVHD: A case report. Presented at Pediatric CRRT, Orlando, 2004 Pasko DA, Churchwell MD, Mueller BA. Duration of continuous hemofiltration and ultrafiltrate production influence on sieving coefficient. Presented at American College of Clinical Pharmacy, Paris 2004
  • 15. Deborah A. Pasko, PharmD, MHA 15 Pasko DA, Churchwell MD, Mueller BA Influence of Time on Multi-flow 60 Filter Life with Continuous Venovenous Hemodialysis (CVVHD). Presented at American College of Clinical Pharmacy, Paris 2004 Pasko DA, Btaiche IF, Nakamura AT, Jain JC, Mueller BA. In-vitro clearance of trace elements via continuous venovenous hemofiltration. J Parenter Enteral Nutr 2004; 28:S7-8 Btaiche IF, Pasko DA, Nakamura AT, Jain JC, Mueller BA. Daily trace element losses via continuous venovenous hemofiltration using an in-vitro model. J Parenter Enteral Nutr 2004; 28:S6-7. Pasko DA, Churchwell MD, Mueller BA. Development of an In vitro Model of Continuous Renal Replacement Therapy (CRRT) Solute Removal. Blood Purification 2004;22:236 Pasko DA, Churchwell MD, Mueller BA. Comparison of Diffusive and Convective Clearance with AN69 and Polysulfone Hemodiafilters in CVVH and CVVHD. Blood Purification 2004;22:242 Pasko DA, Churchwell MD, Mueller BA. Influence of Ultrafiltrate Production Rate on Sieving Coefficient (SC) in Continuous Venovenous Hemofiltration (CVVH). Blood Purification 2004;22:241 Pasko DA, Mottes TA, Mueller BA. Conditioning of blood prime using Diapact® - based CVVHD for pediatric patients. Blood Purification 2003;21:201 Mottes TA, Pasko DA, Mueller BA. Conditioning of blood prime using Prisma® - based CVVHD for pediatric patients. Blood Purification 2003;21:200 O’Toole J, Pasko DA, Swartz R. Citrate Anticoagulation Improves Filter Longevity and Uninterrupted Continuous Renal Replacement Therapy in Severe Acute Renal Failure. Blood Purification 2003;21:197 REVIEWER 2002/2003/2006 American Journal of Hospital Pharmacy 2002/2003 Annals of Pharmacotherapy 2003 The Journal of Pharmacy Technology 2003, 2008 Pediatric Critical Care GRANTS
  • 16. Deborah A. Pasko, PharmD, MHA 16 02/2008 “A Phase II Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Study to Determine the Pharmacodynamics of Sodium Nitroprusside During Prolonged-Infusion in Pediatric Subjects.” Site Primary Investigator: Thomas Shanley, MD Site Co-Investigator: Deborah Pasko Sponsor: National Institute of Child Health and Human Development NICHD-2003-09-LT Accepted 02/2008. 3% salary support 10/2007 “Sedation Management in Pediatric Patients with Acute Respiratory Failure” A Multicenter Trial Site Primary Investigator: Thomas Shanley, MD Site Co-Investigator: Deborah Pasko Sponsor: National Institute of Health, R01 Accepted 12/2007. Patient enrollment starting Spring, 2009. 3% salary support 09/2005 “Using Role-exchanging within a Multidisciplinary Triad of Health Professionals to Improve Patient Medication Safety in a Pediatric Hospital” Primary Investigator: Chris Dickinson, MD Co-Investigator: Deborah A. Pasko Sponsor: National Patient Safety Foundation $100,000. Status: not Funded 12/2003-06/2004 “Pharmacokinetics of Cidecin During Continuous Renal Replacement Therapy” Primary Investigator: Bruce A. Mueller Co-Investigator: Deborah A. Pasko Sponsor: Cubist Pharmaceuticals $25,715. Status: funded 04/2004-04/2005 “Trace Mineral Clearance by CRRT” Primary Investigator: Bruce A. Mueller Co-Investigator: Deborah A. Pasko, Imad Btaiche Sponsor: National Kidney Foundation of Michigan $12,361. Status: Funded 06/2002-06/2003 American College of Clinical Pharmacy Critical Care Fellowship “Longitudinal Hemodiafilter Performance in Convective and Diffusive Modes Using a Multiflow 60 and HF 400 Hemodiafilter” Primary Investigator: Bruce A. Mueller, Co-Investigator: Deborah A. Pasko Sponsor: American College of Clinical Pharmacy, Bayer Pharmaceuticals $22,500, Status: funded 06/2002-06/2003 “Longitudinal Hemodiafilter Performance in Convective and Diffusive Modes Using a CT-190 and F-80 Hemodiafilter”
  • 17. Deborah A. Pasko, PharmD, MHA 17 Primary Investigator: Bruce A. Mueller, Co-Investigator: Deborah A. Pasko Sponsor: National Kidney Foundation of Michigan $25,000, Status: funded 01/2002-01/2003 “Longitudinal Hemodiafilter Performance in Convective and Diffusive Modes Using a Multiflow 60 and F70NR Hemodiafilter” Primary Investigator: Bruce A. Mueller, Co-Investigator: Deborah A. Pasko Sponsor: University of Michigan College of Pharmacy Clinical Research Resource Committee $25,000, Status: funded 01/2003 "In Vitro Hemodialysis Research Support" Principal Investigator Bruce A. Mueller, Co-Investigator Deborah Pasko Material support of a Dialog Hemodialysis machine. Sponsor: B. Braun Medical Inc. Bethlehem, PA $25,000, Status: funded 01/2003 "In Vitro Hemofiltration Research Support" Principal Investigator, Bruce A. Mueller, Co-Investigator Deborah Pasko Material support of a Diapact Hemofiltration machine. Sponsor: B. Braun Medical Inc. Bethlehem, PA $25,000, Status: funded “Longitudinal Hemodiafilter Performance in Convective and Diffusive Modes Using a Minifilter Plus Hemodiafilter” Primary Investigators: Bruce A. Mueller, William A. Smoyer Co-Investigator: Diane Cappellety, Deborah A. Pasko Sponsor: Renal Research Institute $25,000. Status: not funded. “Development of an In Vitro Pharmacodynamic Antibiotic Model in Pediatric Hemodialysis” Primary Investigators: Bruce A. Mueller, William A. Smoyer Co-Investigator: Diane Cappellety, Deborah A. Pasko Sponsor: Renal Research Institute $27,510. Status: not funded “Development of an In Vitro Pharmacodynamic Antibiotic Model in Hemodialysis” Primary Investigators: Bruce A. Mueller Co-Investigator: Diane Cappellety, Deborah A. Pasko Sponsor: National Kidney Foundation of Michigan $27,093. Status: not funded
  • 18. Deborah A. Pasko, PharmD, MHA 18 “Amelioration of AN69-induced bradykinin release in CRRT by blood prime pre- dialysis” Primary Investigator: Deborah A. Pasko Co-Investigator: Bruce A. Mueller, Alvin Schmaier Sponsor: Society of Critical Care Medicine $50,000. Status: Not funded